Precision Biosciences Inc (NASDAQ: DTIL) stock jumped 2.61% on Monday to $0.45 against a previous-day closing price of $0.44. With 0.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.98 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4695 whereas the lowest price it dropped to was $0.4400. The 52-week range on DTIL shows that it touched its highest point at $1.57 and its lowest point at $0.28 during that stretch. It currently has a 1-year price target of $2.62. Beta for the stock currently stands at 1.51.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DTIL was up-trending over the past week, with a rise of 30.61%, but this was up by 50.89% over a month. Three-month performance dropped to -1.54% while six-month performance fell -42.83%. The stock lost -71.46% in the past year, while it has lost -62.35% so far this year. A look at the trailing 12-month EPS for DTIL yields -0.73 with Next year EPS estimates of -0.49. For the next quarter, that number is -0.07. This implies an EPS growth rate of 60.47% for this year and 3.02% for next year.
Float and Shares Shorts:
At present, 110.96 million DTIL shares are outstanding with a float of 92.96 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.61 million, which was 0.52% higher than short shares on Sep 28, 2023. In addition to Mr. Michael Amoroso as the firm’s President, CEO & Director, Mr. John Alexander Kelly R.Ph. serves as its CFO & Principal Accounting Officer.
Through their ownership of 43.77% of DTIL’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.64% of DTIL, in contrast to 15.75% held by mutual funds. Shares owned by individuals account for 13.14%. As the largest shareholder in DTIL with 5.84% of the stake, Capital Research & Management Co holds 6,715,043 shares worth 6,715,043. A second-largest stockholder of DTIL, The Vanguard Group, Inc., holds 4,693,076 shares, controlling over 4.08% of the firm’s shares. Acadian Asset Management LLC is the third largest shareholder in DTIL, holding 3,148,243 shares or 2.74% stake. With a 5.84% stake in DTIL, the American Funds Small Cap World Fu is the largest stakeholder. A total of 6,715,043 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.12% of DTIL stock, is the second-largest Mutual Fund holder. It holds 2,436,960 shares valued at 0.75 million. JPMorgan Funds – Thematics – Gene holds 1.36% of the stake in DTIL, owning 1,563,179 shares worth 0.48 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DTIL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DTIL analysts setting a high price target of $3.00 and a low target of $2.00, the average target price over the next 12 months is $2.63. Based on these targets, DTIL could surge 566.67% to reach the target high and rise by 344.44% to reach the target low. Reaching the average price target will result in a growth of 484.44% from current levels.
Summary of Insider Activity:
Insiders traded DTIL stock several times over the past three months with 3 Buys and 0 Sells. In these transactions, 16,569 shares were bought while 0 shares were sold. The number of buy transactions has increased to 23 while that of sell transactions has risen to 5 over the past year. The total number of shares bought during that period was 603,566 while 89,776 shares were sold.